Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
1st-line treatment with R-CHOP-14 or R-CHOP-21 in patients with high-grade non-Hodgkin’s lymphoma is similarly effective: Date from the German prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Mohm, J., Rauh, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2014.

Blood 124(21), 4406.

Abstract

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: ASH / Journal: Blood
TLN
2014
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.

Knauf, W., Abenhardt, W., Dörfel, S., Meyer, D., Grugel, R., Münz, M., Hartmann, H., Marschner, N., 2014.

Hematol Oncol. doi:10.1002/hon.2139

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Hematological Oncology
TLN
2014
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany–data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).

Knauf, W., Abenhardt, W., Aldaoud, A., Nusch, A., Grugel, R., Münz, M., Hartmann, H., Marschner, N., TLN Study Group, 2014.

Oncol Res Treat 37, 635–644. doi:10.1159/000368315

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Oncology Research and Treatment
TLN
2014
A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy.

Kasper, S., Moehler, M., Hegewisch-Becker, S., Overkamp, F., Bechstein, W.O., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Seehofer, D., Voehringer, M., Geissler, M., Greil, R., Heike, M., Heinemann, V., Lordick, F., Galle, P.R., Schimanski, C.C., 2014.

J Clin Oncol 32:5s(suppl; abstr TPS3658). doi: 10.1200/jco.2014.32.15_suppl.tps3658

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: GI (ASCO) / Journal: Journal of Clinical Oncology
LICC
2014
Prediction of second-line therapy response by plasma proteins in patients with metastatic renal cell carcinoma.

Hölters, S., Ohlmann, C., Bergmann, L., Grünwald, V., Keilholz, U., Staehler, M., Fecher-Trost, C., Schalkowsky, P., Schmerler, D., Junker, K., 2015.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: SWDGU / Journal: -
MARC-2
2014
Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma.

Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2014.

AACR (San Diego) 901.

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: AACR / Journal: -
MARC-2
2014
Wirksamkeit erneuter Anti-HER2-Therapie mit Herceptin® in der klinischen Routine bei erstem Rezidiv und/oder erster Metastasierung des HER2-positiven Mammakarzinoms – 4. Interimanalyse der nichtinterventionellen Studie (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014.

Senologie 11(02), A50(P027). doi:10.1055/s-0034-1375409

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
Herceptin-NIS
2014
Efficacy of anti-HER2 ReTherapy with Herceptin® at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine – 4th interim analysis of the non-interventional study (NIS) ML21589.

Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014.

Ann Oncol 25(suppl4), iv131 (400P). doi:10.1093/annonc/mdu329.49

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
Herceptin-NIS
2014
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.

Goehler, T., Woerns, M.A., Hebart, H.F., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A.H., Wierecky, J., Galle, P.R., Dhensaw, C., Moehler, M.H., Schimanski, C.C., 2014.

J Clin Oncol 32 (suppl; abstr e20724). doi: 10.1200/jco.2014.32.15_suppl.e20724

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
DERMATUX
2014
Effectiveness of 1st-line treatment options in mRCC – a German RCC-Registry evaluation.

Goebell, P.J., Müller, L., Lück, A., Overkamp, F., Vogt, M., Marschner, N., 2014.

J Clin Oncol, ASCO GU, San Francisco 32, (suppl.4; abstr 429). doi:10.1200/jco.2014.32.4_suppl.429

Abstract

Download

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: GCS (ASCO) / Journal: Journal of Clinical Oncology
TNK
2014